Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms

Leukemia Research

Volumn 35, Issue 4, 2011, Pages 459-464

  Spanoudakis, Emmanouil ^a   Bazdiara, Ioanna ^a   Pantelidou, Despoina ^a   Kotsianidis, Ioannis ^a   Papadopoulos, Vasilios ^a   Margaritis, Dimitrios ^a   Xanthopoulidis, George ^a   Moustakidis, Eleftherios ^a   Mantzourani, Stamatia ^a   Bourikas, George ^a   Tsatalas, Costas ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

JAK2V617F; PhnegMPN; Telomerase Activity; Telomeres

Indexed keywords

MESSENGER RNA; TELOMERASE;

ARTICLE; CD34 SELECTION; CHILD; CHROMOSOME 13Q; CHROMOSOME 20Q; CHROMOSOME SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; MYELOPROLIFERATIVE DISORDER; PHENOTYPE; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; TELOMERE; TRISOMY; UPREGULATION;

BONE MARROW CELLS; CELLS, CULTURED; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE; TELOMERE;

EID: 79952363751     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.07.042     Document Type: Article

References (40)

1. Hande M.P., Samper E., Lansdorp P., Blasco M.A. Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice. J Cell Biol 1999, 144:589-601.
2. Lansdorp P.M. Telomeres, stem cells, and hematology. Blood 2008, 111:1759-1766.
3. Lansdorp P.M. Repair of telomeric DNA prior to replicative senescence. Mech Ageing Dev 2000, 118:23-34.
4. Feldser D.M., Hackett J.A., Greider C.W. Telomere dysfunction and the initiation of genome instability. Nat Rev Cancer 2003, 3:623-627.
5. Hackett J.A., Feldser D.M., Greider C.W. Telomere dysfunction increases mutation rate and genomic instability. Cell 2001, 106:275-286.
6. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
7. Bartolovic K., Balabanov S., Berner B., Buhring H.J., Komor M., Becker S., et al. Clonal heterogeneity in growth kinetics of CD34+CD38- human cord blood cells in vitro is correlated with gene expression pattern and telomere length. Stem Cells 2005, 23:946-957.
8. Van Ziffle J.A., Baerlocher G.M., Lansdorp P.M. Telomere length in subpopulations of human hematopoietic cells. Stem Cells 2003, 21:654-660.
9. Drummond M.W., Balabanov S., Holyoake T.L., Brummendorf T.H. Concise review: telomere biology in normal and leukemic hematopoietic stem cells. Stem Cells 2007, 25:1853-1861.
10. Samper E., Fernandez P., Eguia R., Martin-Rivera L., Bernad A., Blasco M.A., et al. Long-term repopulating ability of telomerase-deficient murine hematopoietic stem cells. Blood 2002, 99:2767-2775.
11. Mitchell J.R., Wood E., Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999, 402:551-555.
12. Weng N.P., Hodes R.J. The role of telomerase expression and telomere length maintenance in human and mouse. J Clin Immunol 2000, 20:257-267.
13. Brummendorf T.H., Balabanov S. Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover. Leukemia 2006, 20:1706-1716.
14. Hartmann U., Brummendorf T.H., Balabanov S., Thiede C., Illme T., Schaich M. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica 2005, 90:307-316.
15. Ohyashiki K., Ohyashiki J.H., Fujimura T., Kawakubo K., Shimamoto T., Saito M., et al. Telomere shortening in leukemic cells is related to their genetic alterations but not replicative capability. Cancer Genet Cytogenet 1994, 78:64-67.
16. Kleideiter E., Bangerter U., Schwab M., Boukamp P., Koscielniak E., Klotz U., et al. Telomeres and telomerase in paediatric patients with T-cell acute lymphoblastic leukaemia (T-ALL). Leukemia 2005, 19:296-298.
17. Brummendorf T.H., Maciejewski J.P., Mak J., Young N.S., Lansdorp P.M. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood 2001, 97:895-900.
18. Ohyashiki J.H., Ohyashiki K., Fujimura T., Kawakubo K., Shimamoto T., Iwabuchi A., et al. Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 1994, 54:3557-3560.
19. Ohyashiki J.H., Iwama H., Yahata N., Ando K., Hayashi S., Shay J.W., et al. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin Cancer Res 1999, 5:1155-1160.
20. Beier F., Balabanov S., Buckley T., Dietz K., Hartmann U., Rojewski M., et al. Accelerated telomere shortening in glycosylphosphatidylinositol (GPI)-negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH. Blood 2005, 106:531-533.
21. Karadimitris A., Araten D.J., Luzzatto L., Notaro R. Severe telomere shortening in patients with paroxysmal nocturnal hemoglobinuria affects both GPI- and GPI+ hematopoiesis. Blood 2003, 102:514-516.
22. Ricca I., Rocci A., Drandi D., Francese R., Compagno M., Lobetti Bodoni C., et al. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia 2007, 21:697-705.
23. Roos G., Krober A., Grabowski P., Kienle D., Buhler A., Dohner H., et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 2008, 111:2246-2252.
24. Wu K.D., Orme L.M., Shaughnessy J., Jacobson J., Barlogie B., Moore M.A. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 2003, 101:4982-4989.
25. Brummendorf T.H., Rufer N., Holyoake T.L., Maciejewski J., Barnett M.J., Eaves C.J., et al. Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. Ann N Y Acad Sci 2001, 938:293-303.
26. Campbell L.J., Fidler C., Eagleton H., Peniket A., Kusec R., Gal S., et al. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 2006, 20:671-679.
27. Ohyashiki K., Ohyashiki J.H., Iwama H., Hayashi S., Shay J.W., Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia 1997, 11:190-194.
28. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006, 240-24532.
29. Ferraris A.M., Pujic N., Mangerini R., Rapezzi D., Gallamini A., Racchi O., et al. Clonal granulocytes in polycythaemia vera and essential thrombocythaemia have shortened telomeres. Br J Haematol 2005, 130:391-393.
30. Terasaki Y., Okumura H., Ohtake S., Nakao S. Accelerated telomere length shortening in granulocytes: a diagnostic marker for myeloproliferative diseases. Exp Hematol 2002, 30:1399-1404.
31. Ferraris A.M., Mangerini R., Pujic N., Racchi O., Rapezzi D., Gallamini A., et al. High telomerase activity in granulocytes from clonal polycythemia vera and essential thrombocythemia. Blood 2005, 105:2138-2140.
32. Bernard L., Belisle C., Mollica L., Provost S., Roy D.C., Gilliland D.G., et al. Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms. Leukemia 2009, 23:287-291.
33. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
34. Drummond M.W., Balabanov S., Holyoake T.L., Brummendorf T.H. Concise review: Telomere biology in normal and leukemic hematopoietic stem cells. Stem Cells 2007, 25:1853-1861.
35. Asimakopoulos F.A., Holloway T.L., Nacheva E.P., Scott M.A., Fenaux P., Green A.R. Detection of chromosome 20q deletions in bone marrow metaphases but not peripheral blood granulocytes in patients with myeloproliferative disorders or myelodysplastic syndromes. Blood 1996, 87:1561-1570.
36. Goldman J.M. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 2005, 352:1744-1746.
37. Vannucchi A.M., Antonioli E., Guglielmelli P., Pardanani A., Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2009, 22:1299-1307.
38. Passamonti F., Rumi E. Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica 2009, 94:7-10.
39. Westwood N.B., Gruszka-Westwood A.M., Pearson C.E., Delord C.F., Green A.R., Huntly B.J., et al. The incidences of trisomy 8, trisomy 9 and D20S108 deletion in polycythaemia vera: an analysis of blood granulocytes using interphase fluorescence in situ hybridization. Br J Haematol 2000, 110:839-846.
40. Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia 2008, 22:1841-1848.